Trial Designs And Outcomes In Dementia Therapeutic Research
Download Trial Designs And Outcomes In Dementia Therapeutic Research full books in PDF, epub, and Kindle. Read online free Trial Designs And Outcomes In Dementia Therapeutic Research ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Author | : Kenneth Rockwood |
Publisher | : CRC Press |
Total Pages | : 324 |
Release | : 2005-11-23 |
Genre | : Medical |
ISBN | : 0203340655 |
Given the increased attention of clinicians, researchers, and the pharmaceutical industry to the management and treatment of dementia not only in the elderly but also in increasingly younger populations, the demands for effective evidence-based pharmaceutical control of dementia and quantitative assessment of outcomes have increased. From the first steps in the early 1960s to the controversial landmark paper of Summers and colleagues to the most recent trials, it is clear both that much progress has been made and that much remains to be done. This book is written to take stock of what is now usefully known and to speculate on directions for the future.
Author | : National Academies of Sciences, Engineering, and Medicine |
Publisher | : National Academies Press |
Total Pages | : 181 |
Release | : 2017-10-05 |
Genre | : Medical |
ISBN | : 0309459591 |
Societies around the world are concerned about dementia and the other forms of cognitive impairment that affect many older adults. We now know that brain changes typically begin years before people show symptoms, which suggests a window of opportunity to prevent or delay the onset of these conditions. Emerging evidence that the prevalence of dementia is declining in high-income countries offers hope that public health interventions will be effective in preventing or delaying cognitive impairments. Until recently, the research and clinical communities have focused primarily on understanding and treating these conditions after they have developed. Thus, the evidence base on how to prevent or delay these conditions has been limited at best, despite the many claims of success made in popular media and advertising. Today, however, a growing body of prevention research is emerging. Preventing Cognitive Decline and Dementia: A Way Forward assesses the current state of knowledge on interventions to prevent cognitive decline and dementia, and informs future research in this area. This report provides recommendations of appropriate content for inclusion in public health messages from the National Institute on Aging.
Author | : National Academies of Sciences Engineering and Medicine |
Publisher | : |
Total Pages | : |
Release | : 2022-04-26 |
Genre | : |
ISBN | : 9780309495035 |
As the largest generation in U.S. history - the population born in the two decades immediately following World War II - enters the age of risk for cognitive impairment, growing numbers of people will experience dementia (including Alzheimer's disease and related dementias). By one estimate, nearly 14 million people in the United States will be living with dementia by 2060. Like other hardships, the experience of living with dementia can bring unexpected moments of intimacy, growth, and compassion, but these diseases also affect people's capacity to work and carry out other activities and alter their relationships with loved ones, friends, and coworkers. Those who live with and care for individuals experiencing these diseases face challenges that include physical and emotional stress, difficult changes and losses in their relationships with life partners, loss of income, and interrupted connections to other activities and friends. From a societal perspective, these diseases place substantial demands on communities and on the institutions and government entities that support people living with dementia and their families, including the health care system, the providers of direct care, and others. Nevertheless, research in the social and behavioral sciences points to possibilities for preventing or slowing the development of dementia and for substantially reducing its social and economic impacts. At the request of the National Institute on Aging of the U.S. Department of Health and Human Services, Reducing the Impact of Dementia in America assesses the contributions of research in the social and behavioral sciences and identifies a research agenda for the coming decade. This report offers a blueprint for the next decade of behavioral and social science research to reduce the negative impact of dementia for America's diverse population. Reducing the Impact of Dementia in America calls for research that addresses the causes and solutions for disparities in both developing dementia and receiving adequate treatment and support. It calls for research that sets goals meaningful not just for scientists but for people living with dementia and those who support them as well. By 2030, an estimated 8.5 million Americans will have Alzheimer's disease and many more will have other forms of dementia. Through identifying priorities social and behavioral science research and recommending ways in which they can be pursued in a coordinated fashion, Reducing the Impact of Dementia in America will help produce research that improves the lives of all those affected by dementia.
Author | : National Academies of Sciences Engineering and Medicine |
Publisher | : |
Total Pages | : |
Release | : 2021-11-23 |
Genre | : |
ISBN | : 9780309154291 |
Author | : A. Claudio Cuello |
Publisher | : Springer Science & Business Media |
Total Pages | : 337 |
Release | : 2007-12-22 |
Genre | : Medical |
ISBN | : 0387715223 |
The need for effective therapy to treat Alzheimer’s disease is greater than ever, but there is still no drug therapy that can stop or reverse the progression of the disease. There is, however, a great deal of anticipation over the imminent development of effective therapies as a result of the identification of promising targets for drug development. This book investigates these targets and examines ongoing strategies to develop effective therapies for this devastating neurodegenerative condition.
Author | : Bette R Bonder |
Publisher | : F.A. Davis |
Total Pages | : 700 |
Release | : 2008-10-31 |
Genre | : Medical |
ISBN | : 0803622406 |
The ideal resource for rehabilitation professionals who are working with or preparing to work with older adults! It describes the normal aging process, illustrates how health and social factors can impede an aging person’s abilities, and demonstrates how to develop mechanisms for maximizing the well-being of older adults.
Author | : Jose L. Molinuevo |
Publisher | : Elsevier Health Sciences |
Total Pages | : 204 |
Release | : 2013-05-28 |
Genre | : Medical |
ISBN | : 1455772038 |
This issue of Medical Clinics covers the important advances surrounding the early intervention of Alzheimer's Disease. Guest edited by world-renowned experts from around the world, the topics covered will include evaluation of new diagnostic criteria, CSF biomarkers, diagnostic imaging, neurocognitive approaches, breaking clinical trials and more.
Author | : Serge Gauthier |
Publisher | : CRC Press |
Total Pages | : 410 |
Release | : 2006-11-22 |
Genre | : Medical |
ISBN | : 0203931718 |
The third edition of this successful textbook has been completely updated throughout and includes new chapters on electrophysiological tests, biological markers, global staging measures, and management of neuropsychiatric symptoms. There has been steady progress in our understanding of the natural history, prognostic factors and treatments for Alzh
Author | : E. Beghi |
Publisher | : Karger Medical and Scientific Publishers |
Total Pages | : 180 |
Release | : 2016-07-26 |
Genre | : Medical |
ISBN | : 3318058653 |
Most neurological disorders are chronic and aging-related. With the increase of life expectancy their incidence and prevalence will grow in the decades to come, which in turn will increase the load on medical and social systems worldwide. There is thus a desperate need for successful preventive and therapeutic measures based on randomized clinical trials (RTCs) conducted by independent organizations. This book provides a compendium relating most of the principles of reliable RTCs to specific neurological diseases. Contributed by specialized neurologists, the articles touch on important aspects of RCTs with a clear critical approach, highlighting their limitations as well as giving recommendations for their planning and conducting to address the variable genotypic and phenotypic aspects of neurological conditions. Consideration is also given to combining the clinical impact of the study results with patients’ values and the interests of pharmaceutical companies. Neurologists involved in clinical trials will certainly benefit from this book, which should become a basic text for all neurological courses dealing with evidence-based neurology.
Author | : Jeffrey Cummings |
Publisher | : Cambridge University Press |
Total Pages | : 575 |
Release | : 2022-03-31 |
Genre | : Business & Economics |
ISBN | : 1108838669 |
Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.